Sangamo Shares Plummet as Pfizer Ends Partnership
Sangamo Therapeutics stock drops 50% following Pfizer's termination of their co-development agreement. Discover the impact on Sangamo's future prospects.
Topic
Sangamo Therapeutics
A collection of 7 issues
Sangamo Shares Plummet After Pfizer Exit
Sangamo Therapeutics shares plunged 50% as Pfizer ends collaboration on hemophilia drug, impacting biotech stocks. Discover the implications for investors.
Sangamo Shares Plunge as Pfizer Exits Partnership
Sangamo Therapeutics' stock plummeted by over 50% following Pfizer's decision to withdraw from their joint agreement. Explore the impact on biotech stocks.
Sangamo Shares Plummet After Pfizer Ends Collaboration
Sangamo Therapeutics' stock nosedives over 50% as Pfizer halts partnership on hemophilia drug. Discover the implications for Sangamo's future and investor concerns.
Sangamo Stock Falls as Pfizer Ends Hemophilia Collaboration
Sangamo Therapeutics' stock dropped sharply after Pfizer announced it is ending their collaboration on a groundbreaking hemophilia drug. Discover the impact on biotech stocks.
Sangamo Stock Drops 67% After Pfizer Partnership Ends
Sangamo Therapeutics' shares nosedived by 67% following Pfizer's decision to terminate their hemophilia A gene therapy collaboration. Explore the impact on biotech stocks.
Sangamo Therapeutics Stock Plummets 67% After Pfizer Ends Hemophilia A Partnership
Sangamo Therapeutics Inc. stock dropped 67% as Pfizer Inc. terminated its collaboration on gene therapy for hemophilia A, impacting Sangamo's financial outlook.